BrainEver

📍 Paris, France🗓 Founded 2015👥 27 employees💰 Last funded Feb 2025
Biotechnology Research🌐 brainever.fr
Website LinkedIn
BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness. Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons. BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology. Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025. Follow us!
7
Total investors
0
Early stage
1
Mid stage
6
Late stage
2015
Founded

Investors

7 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
7
Investor activity2020–2025 · investors recorded per year
202012024520251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in BrainEver?
BrainEver has 7 investors on record on gritt.io, 1 mid-stage and 6 late-stage investors.
When did BrainEver last raise funding?
The most recent investment in BrainEver recorded on gritt.io was in February 2025.
When was BrainEver founded?
BrainEver was founded in 2015.
What industry is BrainEver in?
BrainEver operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is BrainEver based?
BrainEver is headquartered in Paris, France.